Register for our free email digests:
Latest From Mediolanum Farmaceutici SRL
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.
As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December.
Three rapid-fire clinical setbacks scuttled a planned merger between BioCryst and Presidio that would have created a new competitor in the hepatitis C space. Now, BioCryst is retrenching with a staff cut and narrower R&D focus.
Italian life sciences seed capital firm Eporgen Venture has used a network of wealthy individuals in Italy to fund a group of new biotech companies, and has entered into its first transaction, selling Genovax’s potential cancer vaccine to Italian pharmaceutical company Mediolanum.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Gynecological, Urological
- Western Europe
- Parent & Subsidiaries
- ObsEva SA
- Senior Management
Ernest Loumaye, MD, PhD, CEO
Timothy Adams, CFO
Jean-Pierre Gotteland , PhD, CSO
Ben Tang, VP, Commercial & Bus. Dev.
- Contact Info
Chemin des Aulx 12
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.